Pear Therapeutics, Inc. signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.
Pear Therapeutics announced on 21 March it signed an agreement with SoftBank Corp. to develop a Japan-focused digital therapeutic for treating sleep/wake disorders.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?